


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound represented by Formula I:



or a pharmaceutically acceptable salt or hydrate thereof, wherein:


Ar is phenyl or naphthyl;

$m = 1, 2, 3, \text{ or } 4;$

$n = 0, 1, 2, 3, \text{ or } 4;$

X is a bond, O, NH or S(O) $_k$, wherein k is 0, 1 or 2;

A is selected from the group consisting of: $-\text{CO}_2\text{H}$, $-\text{PO}_3\text{H}_2$, $-\text{PO}_2\text{H}_2$, $-\text{SO}_3\text{H}$, $-\text{PO}(\text{R}^8)\text{OH}$,



each R¹ is independently selected from the group consisting of: hydrogen, halo, hydroxy, -CO₂H, C₁-4alkyl, C₁-4alkoxy, C₁-4alkylthio and aryl, wherein said C₁-4alkyl, C₁-4alkoxy and C₁-4alkylthio are each optionally substituted from one up to the maximum number of substitutable positions with halo and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C₁-4alkyl, or

when m is 2, 3, or 4, two R¹ groups on adjacent carbon atoms may be joined together to form a double bond;

each R³ is independently selected from the group consisting of: hydrogen, halo, hydroxy, -CO₂H, C₁-4alkyl, C₁-4alkoxy, C₁-4alkylthio and aryl, wherein said C₁-4alkyl, C₁-4alkoxy and C₁-4alkylthio are each optionally substituted from one up to the maximum number of substitutable positions with halo and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C₁-4alkyl, or

when n is 2, 3, or 4, two R³ groups on adjacent carbon atoms may be joined together to form a double bond;

R² and R⁴ are each independently selected from the group consisting of: hydrogen, halo, hydroxy, -CO₂H, C₁-4alkyl, C₁-4alkoxy, C₁-4alkylthio and aryl, wherein said C₁-4alkyl, C₁-4alkoxy and C₁-4alkylthio are each optionally substituted from one up to the maximum number of substitutable positions with halo and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C₁-4alkyl;

or R¹ and R² or R³ and R⁴ residing on the same carbon atom may optionally be joined together to form a carbonyl group,

each R⁵ is independently selected from the group consisting of: halo, aryl, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkoxy, C₁₋₆alkylthio and C₃₋₆cycloalkoxy, said C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkoxy, C₁₋₆alkylthio and C₃₋₆cycloalkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

R⁸ is selected from the group consisting of: C₁₋₄alkyl and aryl, wherein said C₁₋₄alkyl is optionally substituted with 1-3 halo groups and aryl is optionally substituted with 1-5 substituents independently selected from the group consisting of: halo, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkoxy, C₁₋₄alkylthio and C₃₋₆cycloalkoxy, said C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkoxy, C₁₋₄alkylthio and C₃₋₆cycloalkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

C is selected from the group consisting of:

- (1) C₁₋₈alkyl, C₁₋₈alkoxy, -(C=O)-C₁₋₆alkyl or -CHOH-C₁₋₆alkyl, said C₁₋₈alkyl, C₁₋₈alkoxy, -(C=O)-C₁₋₆alkyl and -CHOH-C₁₋₆alkyl optionally substituted with phenyl, and
- (2) phenyl or HET, each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, phenyl, C₁₋₄alkyl, C₁₋₄alkoxy and aralkyl, said C₁₋₄alkyl and C₁₋₄alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl and the aryl portion of aralkyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo, C₁₋₄alkyl and C₁₋₄alkoxy, said C₁₋₄alkyl and C₁₋₄alkoxy optionally substituted with 1-3 halo groups,

or C is not present;

when **C** is not present then **B** is selected from the group consisting of: phenyl, C₅-16alkyl, C₅-16alkenyl, C₅-16alkynyl, -CHOH-C₄-15alkyl, -CHOH-C₄-15alkenyl, -CHOH-C₄-15alkynyl, C₄-15alkoxy, -O-C₄-15alkenyl, -O-C₄-15alkynyl, C₄-15alkylthio, -S-C₄-15alkenyl, -S-C₄-15alkynyl, -CH₂-C₃-14alkoxy, -CH₂-O-C₃-14alkenyl, -CH₂-O-C₃-14alkynyl, -(C=O)-C₄-15alkyl, -(C=O)-C₄-15alkenyl, -(C=O)-C₄-15alkynyl, -(C=O)-O-C₃-14alkyl, -(C=O)-O-C₃-14alkenyl, -(C=O)-O-C₃-14alkynyl, -(C=O)-N(R⁶)(R⁷)-C₃-14alkyl, -(C=O)-N(R⁶)(R⁷)-C₃-14alkenyl, -(C=O)-N(R⁶)(R⁷)-C₃-14alkynyl, -N(R⁶)(R⁷)-(C=O)-C₃-14alkyl, -N(R⁶)(R⁷)-(C=O)-C₃-14alkenyl and -N(R⁶)(R⁷)-(C=O)-C₃-14alkynyl,

when **C** is phenyl or HET then **B** is selected from the group consisting of: C₁-6alkyl, C₁-5alkoxy, -(C=O)-C₁-5alkyl, -(C=O)-O-C₁-4alkyl, -(C=O)-N(R⁶)(R⁷)-C₁-4alkyl, -(C=O)-, -(CHOH)-, phenyl and HET, said phenyl and HET each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, phenyl, C₁-4alkyl, C₁-4alkoxy and aralkyl, said C₁-4alkyl and C₁-4alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl and the aryl portion of aralkyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo, C₁-4alkyl and C₁-4alkoxy, said C₁-4alkyl and C₁-4alkoxy optionally substituted with 1-3 halo groups, and

when **C** is C₁-8alkyl, C₁-8alkoxy, -(C=O)-C₁-6alkyl or -CHOH-C₁-6alkyl then **B** is phenyl or HET, said phenyl and HET each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, phenyl, C₁-4alkyl, C₁-4alkoxy and aralkyl, said C₁-4alkyl and C₁-4alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl and the aryl portion of aralkyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo, C₁-4alkyl and C₁-4alkoxy, said C₁-4alkyl and C₁-4alkoxy optionally substituted with 1-3 halo groups; and

R⁶ and R⁷ are independently selected from the group consisting of: hydrogen, C₁-9alkyl and -(CH₂)_q-phenyl, wherein q is 1 to 5 and phenyl is optionally substituted with 1-5 substituents independently selected from the group consisting of: C₁-3alkyl and C₁-3alkoxy, each optionally substituted with 1-3 halo groups.

2. (original) The compound according to Claim 1 wherein:


Ar is phenyl and

the group **-B-C** is attached to the phenyl ring at the 3- or 4-position.

3. (original) The compound according to Claim 1 wherein X is a bond, m is 2 and n is 2.

4. (original) The compound according to Claim 1 wherein X is selected from O, NH or S, m is 1 and n is 2.

5. (original) The compound according to Claim 1 wherein HET is selected from the group consisting of:




6. (currently amended) The method compound according to Claim 1 wherein **C** is not present and **B** is selected from the group consisting of: C₅-16alkyl, C₅-16alkenyl, C₅-16alkynyl, -CHOH-C₄-15alkyl, -CHOH-C₄-15alkenyl, -CHOH-C₄-15alkynyl, C₄-15alkoxy, -O-C₄-15alkenyl, -O-C₄-15alkynyl, C₄-15alkylthio, -S-C₄-15alkenyl, -S-C₄-15alkynyl, -CH₂-C₃-14alkoxy, -CH₂-O-C₃-14alkenyl, -CH₂-O-C₃-14alkynyl, -(C=O)-C₄-15alkyl, -(C=O)-C₄-15alkenyl, -(C=O)-C₄-15alkynyl, -(C=O)-O-C₃-14alkyl, -(C=O)-O-C₃-14alkenyl, -(C=O)-O-C₃-14alkynyl, -(C=O)-N(R₆)(R₇)-C₃-14alkyl, -(C=O)-N(R₆)(R₇)-C₃-14alkenyl, -(C=O)-N(R₆)(R₇)-C₃-14alkynyl, -N(R₆)(R₇)-(C=O)-C₃-14alkyl, -N(R₆)(R₇)-(C=O)-C₃-14alkenyl and -N(R₆)(R₇)-(C=O)-C₃-14alkynyl.

7. (original) The compound according to Claim 1 wherein **C** is phenyl and **B** is selected from the group consisting of: C₁-6alkyl, C₁-5alkoxy, -(C=O)-C₁-5alkyl, -(C=O)-O-C₁-4alkyl and -(C=O)-N(R⁶)(R⁷)-C₁-4alkyl.


8. (currently amended) The compound ~~accordin~~ according to Claim 1
wherein:

B-C is selected from the group consisting of:

- (1) **B** is C₇-10alkyl and **C** is not present,
- (2) **B** is C₆-9alkoxy and **C** is not present,
- (3) **B** is C₁-6alkyl or C₁-5alkoxy and **C** is phenyl, or
- (4) **B-C** is



or



9. (currently amended) ~~A~~ The compound in accordance with Claim 1
wherein:

when X is a bond then m is 2 and n is 2,

when X is O, NH or S then m is 1 and n is 2,

Ar is phenyl and

the group **-B-C** is attached to the phenyl ring at the 3- or 4-position.

10. (original) The compound in accordance with Claim 9 wherein **C** is not present and **B** is selected from the group consisting of: C₅-16alkyl, C₅-16alkenyl, C₅-16alkynyl, -CHOH-C₄-15alkyl, -CHOH-C₄-15alkenyl, -CHOH-C₄-15alkynyl, C₄-15alkoxy, -O-C₄-15alkenyl, -O-C₄-15alkynyl, C₄-15alkylthio, -S-C₄-15alkenyl, -S-C₄-15alkynyl, -CH₂-C₃-14alkoxy, -CH₂-O-C₃-14alkenyl, -CH₂-O-C₃-14alkynyl, -(C=O)-C₄-15alkyl, -(C=O)-C₄-15alkenyl, -(C=O)-C₄-15alkynyl, -(C=O)-O-C₃-14alkyl, -(C=O)-O-C₃-14alkenyl, -(C=O)-O-C₃-14alkynyl, -(C=O)-N(R⁶)(R⁷)-C₃-14alkyl, -(C=O)-N(R⁶)(R⁷)-C₃-14alkenyl, -(C=O)-N(R⁶)(R⁷)-C₃-14alkynyl, -N(R⁶)(R⁷)-(C=O)-C₃-14alkyl, -N(R⁶)(R⁷)-(C=O)-C₃-14alkenyl and -N(R⁶)(R⁷)-(C=O)-C₃-14alkynyl.


11. (original) The compound in accordance with Claim 10 wherein **C** is not present and **B** is C₇-10alkyl.


12. (original) The compound in accordance with Claim 10 wherein **C** is not present and **B** is C₆-9alkoxy.


13. (original) The compound in accordance with Claim 9 wherein **C** is phenyl and **B** is C₃-6alkyl.


14. (original) The compound in accordance with Claim 9 wherein **A** is selected from the group consisting of: -CO₂H, -PO₃H₂, -PO₂H₂, -SO₃H and -PO(R⁸)OH.


15. (currently amended) A compound selected from the group consisting of:














or a pharmaceutically acceptable salt of any of the above.

16. (original) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

17. (original) The method according to Claim 16 wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.

18. (canceled)

19. (original) The method according to Claim 16 wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis cornea, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocarditis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-

shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.

20 to 27. (canceled)

28. (original) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

29. (original) A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.